Ryvu Therapeutics (RVU) Q3 2024 earnings summary

Executive summary

• Operating revenue for the first nine months of 2024 increased to PLN 73.6m, driven by higher sales, R&D project revenues, and subsidies, notably from BioNTech and Exelixis collaborations.

• Net loss widened to PLN 76.4m from PLN 64.4m year-over-year, mainly due to increased R&D and clinical development spending.

• Cash position strengthened to PLN 176.5m as of September 30, 2024, supported by EIB financing tranches totaling EUR 22m.

• Four Phase II clinical trials for RVU120 are underway, with additional preclinical and discovery programs advancing.

• Significant progress in synthetic lethality and immuno-oncology platforms, with new grants and partnerships secured.

Financial highlights

• Total assets at September 30, 2024: PLN 403.2m, stable year-to-date.

• Cash and equivalents rose to PLN 176.5m from PLN 57.9m at year-end 2023.

• Total liabilities increased to PLN 225.4m (from PLN 143.6m), mainly due to EIB loans.

• Net cash from investing activities was PLN 128.0m, reflecting EIB tranches; operating cash flow was negative PLN 101.5m.

• Net loss per share for the period was PLN -3.30, compared to PLN -2.82 a year earlier.

Outlook and guidance

• Financial position remains strong, with cash and funding sufficient to support planned R&D and clinical activities.

• Future revenues depend on successful commercialization of R&D projects and achieving milestones in collaborations.

• Key objectives include expanding RVU120 clinical development, advancing preclinical programs, and signing new partnerships.